SEC Filings
MacroGenics Selects 3 Mg/Kg Cancer-Trial Dose, Down From 6 Mg/Kg In Earlier Cohort
The company plans to enroll 20 additional clear cell gynecologic cancer patients by year-end 2026.
MacroGenics (MGNX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The company plans to enroll 20 additional clear cell gynecologic cancer patients by year-end 2026.
SEC Filings
Manufacturing-sale proceeds and partner payments added cash as smaller milestones pushed quarterly revenue lower.
SEC Filings
The cancer-drug developer seated a former Terns medical chief and a former Day One R&D head on its Science and Technology Committee.
SEC Filings
The experimental antibody-drug conjugate drew no treatment-related discontinuations in the head and neck cohort, and a pembrolizumab combination study is planned.